In this podcast, Drs. Michelle Kittleson and Jan Griffin provide a practical overview of evaluation and management of transthyretin amyloid cardiomyopathy (ATTR-CM) based on ACC’s 2025 Concise Clinical Guidance document the Transthyretin Cardiac Amyloidosis Evaluation and Management: 2025 ACC Concise Clinical Guidance. The experts elaborate on key takeaways, including identifying cardiac and extra-cardiac features that raise suspicion, outlining the diagnostic pathway and screening strategies, and utilizing current disease-modifying therapies and heart failure management. Guidance on monitoring, determining treatment candidacy, and emerging future therapies is also discussed.

This podcast is supported by an educational grant from BridgeBio.

Related References:

1. Writing Committee, Kittleson MM, Ambardekar AV, et al. Transthyretin Cardiac Amyloidosis Evaluation and Management: 2025 ACC Concise Clinical Guidance. J Am Coll Cardiol. Published online October 31, 2025. doi:10.1016/j.jacc.2025.09.004
2. Margolin E, Stern LK, Argiro A, Rosenthal JL, Urey MA, Alexander KM. Current and Future Treatment Landscape of Transthyretin Amyloid Cardiomyopathy. Cardiol Ther. 2025;14(3):385-401. doi:10.1007/s40119-025-00424-6
3. Porcari A, Cappelli F, Nitsche C, et al. SGLT2 Inhibitor Therapy in Patients With Transthyretin Amyloid Cardiomyopathy. J Am Coll Cardiol. 2024;83(24):2411-2422. doi:10.1016/j.jacc.2024.03.429
4. 4. Maurer M.S., Schwartz J.H., Gundapaneni B., et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018;379:1007-1016.
5. 5. Gillmore J.D., Judge D.P., Cappelli F., et al. Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy. N Engl J Med. 2024;390:132-142.